Key takeaways
Aimovig (erenumab) and Emgality (galcanezumab) are both medications used to prevent migraines, but they have some differences. Aimovig (erenumab) is a calcitonin gene-related peptide (CGRP) receptor antagonist, while Emgality (galcanezumab) is a monoclonal antibody that blocks CGRP, a protein involved with migraine pain. Both are currently available only as brand-name medications that can be injected at home. Aimovig is injected once a month, and the typical dose is 70 mg, which can be increased to 140 mg. Emgality, on the other hand, starts with a 240 mg dose (two injections of 120 mg each) and then continues with 120 mg monthly. Emgality is also approved to treat episodic cluster headaches, while Aimovig is not. Common side effects for Aimovig include injection site reactions and constipation, whereas Emgality can cause injection site reactions, sore throat, and back pain. Both medications require proper training for self-injection and have specific storage instructions.
